Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.
A new analysis of an abandoned trial has resurrected Protagonist's lead asset, but the company has a long way to go and faces some stiff competition.
The US government is trying to change the way Medicare reimburses doctors for office-administered drugs – but whether it will succeed is another story.
Invokana looking for good showing at American College of Cardiology meeting to improve prospects.
Acthar's high price tag has led to slowing sales, but it is patients, not payers, who are leading the backlash.